| Literature DB >> 26540074 |
Chunhua Wang1, Zhenxue Zhang2, Yihai Wang3, Xiangjiu He4.
Abstract
Bioactivity-guided fractionation was used to determine the cytotoxic alkaloids from the toxic plant Peganum harmala. Two novel indole alkaloids, together with ten known ones, were isolated and identified. The novel alkaloids were elucidated to be 2-(indol-3-yl)ethyl-α-L-rhamnopyranosyl-(1 → 6)-β-D-glucopyranoside (2) and 3-hydroxy-3-(N-acetyl-2-aminoethyl)-6-methoxyindol-2-one (3). The cytotoxicity against human leukemia cells was assayed for the alkaloids and some of them showed potent activity. Harmalacidine (compound 8, HMC) exhibited the highest cytotoxicity against U-937 cells with IC50 value of 3.1 ± 0.2 μmol/L. The cytotoxic mechanism of HMC was targeting the mitochondrial and protein tyrosine kinase signaling pathways (PTKs-Ras/Raf/ERK). The results strongly demonstrated that the alkaloids from Peganum harmala could be a promising candidate for the therapy of leukemia.Entities:
Keywords: Peganum harmala; anti-leukemia; cytotoxicity; indole alkaloids; mitochondrial pathway
Mesh:
Substances:
Year: 2015 PMID: 26540074 PMCID: PMC4663518 DOI: 10.3390/toxins7114507
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Alkaloids isolated from P. harmala.
Cytotoxicity of the alkaloids from P. Harmala against human leukemia cells U-937, HL-60, KG1, and HEL, and human embryonic kidney cells HEK-293 (IC50, Mean ± SD, μmol/L).
| Compound | IC50 (μmol/L) | ||||
|---|---|---|---|---|---|
| U-937 | HL-60 | KG1 | HEL | HEK-293 | |
| 1 | 52.1 ± 2.6 | 78.9 ± 3.8 | 23.1 ± 1.4 | 121.3 ± 5.5 | >200 |
| 2 | 80.2 ± 4.5 | 55.3 ± 3.4 | 60.2 ± 2.7 | 131.0 ± 4.9 | >200 |
| 3 | 75.3 ± 2.8 | 36.2 ± 1.1 | >200 | 55.3 ± 3.2 | 122.4 ± 5.7 |
| 4 | 46.1 ± 2.0 | 62.0 ± 2.8 | 47.7 ± 2.3 | 54.6 ± 2.3 | >200 |
| 5 | 23.1 ± 0.9 | 71.2 ± 3.3 | 62.7 ± 2.8 | 20.3 ± 1.1 | >200 |
| 6 | 30.6 ± 1.2 | 60.7 ± 2.9 | 44.5 ± 2.1 | 71.6 ± 2.7 | >200 |
| 7 | 22.3 ± 1.4 | 44.3 ± 2.1 | 56.8 ± 2.5 | 35.2 ± 2.8 | 164.2 ± 8.1 |
| 8 | 3.1 ± 0.2 | 61.3 ± 2.8 | 32.6 ± 1.7 | 25.7 ± 1.1 | >200 |
| 9 | 10.6 ± 0.7 | 55.3 ± 2.4 | 46.8 ± 1.9 | 20.1 ± 1.2 | 156.3 ± 7.2 |
| 10 | 15.3 ± 0.7 | 45.7 ± 2.1 | 56.9 ± 2.3 | 21.2 ± 1.1 | 132.5 ± 4.6 |
| 11 | 49.6 ± 1.9 | 87.3 ± 3.7 | 113.2 ± 5.6 | 68.3 ± 3.0 | >200 |
| 12 | 55.3 ± 1.7 | 93.8± 6.8 | 88.1 ± 3.7 | 120.9 ± 5.5 | >200 |
| Cisplatin | 6.3 ± 0.5 | 13.5 ± 0.4 | 4.1 ± 0.3 | 7.7 ± 0.2 | 120.6 ± 5.7 |
Figure 2HMC initiated apoptosis in U-937 cells through mitochondrial and Caspase cascade. (A) Apoptotic U-937 cells were observed after the cells were stained by Hoechst 33258. (B) Mitochondrial transmembrane potential was reduced in U-937 cells stained by Rodamine123. (C) The ATP level was also reduced in U-937 cells. (D–F) HMC impacted the mRNA levels and protein expressions of Bax and Bcl-2 in U-937 cells leading to the activation of caspase 3. Data are presented as means ± SD of three independent tests. * p < 0.05 versus control, ** p < 0.01 versus control.
Figure 3Apoptosis via Ras/Raf/ERK signaling pathway in U-937 cells after HMC treatment. (A) Cell viability was assessed using MTT method in U-937 cells after pretreated by 10 µmol/L Genistein for 1 h, and then the cells were incubated without or with 2.0 µmol/L HMC for 48 h. (B,C) Expressions of Ras, p-Raf and P-ERK1/2 were detected using Western blot analysis and the quantity results were showed in Figure 3C. Data are presented as means ± SEM of three independent tests. * p < 0.05 versus control, ** p < 0.01 versus control.